Literature DB >> 10378541

Impact of revised stage classification of lung cancer on survival: a military experience.

S A Adebonojo1, A N Bowser, D M Moritz, P C Corcoran.   

Abstract

STUDY
OBJECTIVES: This report reviews results of surgical management of lung cancer at a military medical center using the revised 1997 stage classification and determines the impact of the revised system on survival rates. It also compares our results with the recent reports from Japan and from a large, multinational study involving several institutions.
DESIGN: Retrospective review.
SETTING: Department of Cardiothoracic Surgery, Walter Reed Army Medical Center (WRAMC), Washington, DC. PATIENTS OR PARTICIPANTS: Active military members, their dependents, and eligible retired military members who were admitted to WRAMC for surgical treatment of lung cancer between January 1984 and December 1996.
METHODS: Records of all patients who had surgical resection with intent to cure were reviewed. Data extracted included clinical and pathologic stages according to the 1997 revised stage classification. Survival probabilities for the stages were calculated by the Kaplan-Meier actuarial method. The log rank test was used to compare survival rates between stages and stage subsets. A p value < 0.05 was considered statistically significant. MEASUREMENTS AND
RESULTS: Five hundred fifty-two of the 1,398 patients with primary lung cancers underwent curative surgical resection (39.5%). The operative mortality was 2%. Using the revised 1997 stage classification, the survival rate for stage IA was 77%; IB, 62%; IIA, 57%; IIB, 47%; IIIA, 28%; IIIB, 20%; and IV, 0%. The overall actuarial 5-year and 10-year survival rates were 58% and 45%, respectively (median survival, 3.3 years; mean survival 3.9+/-0.1 years).
CONCLUSIONS: Our results confirm the justification for the recent revisions in the staging system of lung cancer; however, there are still discrepancies that cannot be explained.

Entities:  

Mesh:

Year:  1999        PMID: 10378541     DOI: 10.1378/chest.115.6.1507

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  18 in total

Review 1.  Lung Stereotactic Body Radiation Therapy.

Authors:  Sana Rehman; Michael C Roach; Jeffrey D Bradley; Cliff G Robinson
Journal:  Mo Med       Date:  2015 Sep-Oct

2.  A Pilot Study of Texture Analysis of Primary Tumor [18F]FDG Uptake to Predict Recurrence in Surgically Treated Patients with Non-small Cell Lung Cancer.

Authors:  Masatoyo Nakajo; Megumi Jinguji; Tetsuya Shinaji; Masaya Aoki; Atsushi Tani; Yoshiaki Nakabeppu; Masayuki Nakajo; Masami Sato; Takashi Yoshiura
Journal:  Mol Imaging Biol       Date:  2019-08       Impact factor: 3.488

3.  A new PET/CT volumetric prognostic index for non-small cell lung cancer.

Authors:  Hao Zhang; Kristen Wroblewski; Yulei Jiang; Bill C Penney; Daniel Appelbaum; Cassie A Simon; Ravi Salgia; Yonglin Pu
Journal:  Lung Cancer       Date:  2015-04-09       Impact factor: 5.705

Review 4.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

5.  Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.

Authors:  Shengri Liao; Bill C Penney; Kristen Wroblewski; Hao Zhang; Cassie A Simon; Rony Kampalath; Ming-Chi Shih; Naoko Shimada; Sheng Chen; Ravi Salgia; Daniel E Appelbaum; Kenji Suzuki; Chin-Tu Chen; Yonglin Pu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-23       Impact factor: 9.236

6.  Myelodysplastic syndromes: challenges to improving patient and caregiver satisfaction.

Authors:  B Douglas Smith
Journal:  Am J Med       Date:  2012-07       Impact factor: 4.965

Review 7.  Population-based trends in lung cancer incidence in women.

Authors:  Brian L Egleston; Sibele I Meireles; Douglas B Flieder; Margie L Clapper
Journal:  Semin Oncol       Date:  2009-12       Impact factor: 4.929

Review 8.  Prognostic value of metabolic tumor burden in lung cancer.

Authors:  Piotr Obara; Yonglin Pu
Journal:  Chin J Cancer Res       Date:  2013-12       Impact factor: 5.087

9.  Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer.

Authors:  Ka Wing Ma; Tan To Cheung; Wong Hoi She; Kenneth Siu Ho Chok; Albert Chi Yan Chan; Wing Chiu Dai; Wan Hang Chiu; Chung Mau Lo
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

10.  A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.

Authors:  Mark A Henderson; David J Hoopes; James W Fletcher; Pei-Fen Lin; Mark Tann; Constantin T Yiannoutsos; Mark D Williams; Achilles J Fakiris; Ronald C McGarry; Robert D Timmerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-25       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.